glp-1 obesity drug news october 9 2025 How to Invest in Drugs: Stocks and Funds to Watch 2024 was a record year
Description
As more providers and patients adopt GLP-1s for multiple conditions in 2026, the drug class is becoming relevant to a broader range of long-term health needs
[DOI] [PubMed] [Google Scholar] 88.DeFronzo RA, Ratner RE, Han J, et al
Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice
1 It makes sense once you understand how these drugs actually work
The equivalent injectable dose would therefore be approximately 2mg to 2.4mg weekly, since injectable bioavailability approaches 100%
